# JAK-STAT and IL-17 pathway dysregulation underlies persistent immune dysfunction in ART-experienced people living with HIV in Ghana

**Authors:** Mark Appeaning, Edwin Magomere, Nana Ama Yeboaa Amoako, Kirk Elorm Kouffie, Kesego Tapela, Charles Ochieng’ Olwal, Jones Amo Amponsah, Stella Nartey, Rosalynn Baah-Danquah, Salome Tettey Frimpong, Seyram Tetteh Quarshie, Samuel Efa-Quayson, Francis Broni, Felix E. Nenyewodey, James Abugri, Gloria Akosua Ansa, Evelyn Yayra Bonney, Peter Kojo Quashie

PMC · DOI: 10.3389/fimmu.2026.1753475 · Frontiers in Immunology · 2026-02-10

## TL;DR

This study explores immune dysfunction in HIV patients in Ghana, finding that ART reduces inflammation but leaves chemokine signaling and JAK-STAT pathways dysregulated.

## Contribution

The study identifies specific cytokine and pathway dysregulation in ART-treated HIV patients in West Africa, highlighting potential biomarkers and therapeutic targets.

## Key findings

- ART reduces inflammatory cytokines but increases RANTES and Eotaxin in HIV patients.
- IL-1Ra is a central node in cytokine networks, and IP-10 correlates positively with viral load.
- Persistent chemotactic signaling and impaired JAK-STAT and IL-17 pathways are observed despite ART.

## Abstract

Chronic immune activation and inflammation are central to HIV pathogenesis and persist despite antiretroviral therapy (ART), contributing to non-AIDS comorbidities. The HIV epidemic in West Africa is distinct, marked by the coexistence of HIV-1, HIV-2 in circulation as well as recombinant forms, yet immune responses in this region remain under-investigated. This study examined how ART modulates cytokine and chemokine signaling in Ghanaian people living with HIV (PLWH), with emphasis on biomarkers of immune dysfunction and treatment response.

Plasma concentrations of 25 cytokines and chemokines were quantified using Luminex multiplex assays in 247 participants: ART-naïve (n=141), post-ART at 6-months (n=52) and 12-months (n=23), ART-experienced (n=74), and HIV-negative controls (n=32). Differentially expressed cytokines, cytokine network analysis, and pathway enrichment analyses, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed using R-anchored packages. Correlations between cytokine levels and viral load were also evaluated. Cox proportional hazards regression was applied to identify biomarker of HIV disease progression and predictive modelling using Least Absolute Shrinkage and Selection Operator (LASSO) regression, Random Forest (RF), and Gradient Boosting Machine (GBM).

ART-naïve individuals exhibited elevated pro-inflammatory (IL-6, IL-12/IL-23p40, IL-2, IL-15, IL-2R), and chemotactic (MCP-1, IP-10, MIG) cytokines, alongside reduced IL-1β and IL-1Ra. ART significantly reduced inflammatory cytokines, but paradoxically increased RANTES and Eotaxin. IL-1Ra emerged as the central node in cytokine interaction networks, while IP-10 positively and RANTES negatively correlated with viral load. Lower IL-1β and IL-10 levels predicted virologic control, whereas elevated GM-CSF was linked to persistent viraemia. Machine learning modelling identified RANTES, IP-10, IL-12/IL-23p40, IL-7, and IL-2R as the strongest predictors of viral load. Pathway enrichment analysis revealed upregulation of chemokine-mediated signaling and eosinophil chemotaxis, but downregulation of leukocyte activation, IL-17, and JAK-STAT signaling.

ART attenuates systemic inflammation and partially restores immune balance in PLWH in Ghana, but recovery remains functionally dysregulated, with persistent chemotactic signaling and impaired mucosal and JAK-STAT–mediated immunity. IL-1β, IL-10, GM-CSF, RANTES, and IP-10 emerge as prognostic markers of disease progression and potential targets for adjunctive immunotherapies. These findings underscore the need for immune-modulatory strategies to optimize ART outcomes in West Africa.

## Linked entities

- **Proteins:** IL6 (interleukin 6), IL2 (interleukin 2), IL15 (interleukin 15), IL2RA (interleukin 2 receptor subunit alpha), CCL2 (C-C motif chemokine ligand 2), CXCL10 (C-X-C motif chemokine ligand 10), CXCL9 (C-X-C motif chemokine ligand 9), IL1B (interleukin 1 beta), IL1R1 (interleukin 1 receptor type 1), CCL5 (C-C motif chemokine ligand 5), Ccl11 (C-C motif chemokine ligand 11), IL10 (interleukin 10), CSF2 (colony stimulating factor 2)
- **Diseases:** AIDS (MONDO:0012268)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283] {aka CMK, Humig, MIG, SCYB9, crg-10}, CCL11 (C-C motif chemokine ligand 11) [NCBI Gene 6356] {aka SCYA11}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, IL2RB (interleukin 2 receptor subunit beta) [NCBI Gene 3560] {aka CD122, IL15RB, IMD63, P70-75}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, VN1R17P (vomeronasal 1 receptor 17 pseudogene) [NCBI Gene 441931] {aka GPCR}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, CCR5 (C-C motif chemokine receptor 5) [NCBI Gene 1234] {aka CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}
- **Diseases:** AIDS (MESH:D000163), viremia (MESH:D014766), non-communicable diseases (MESH:D000073296), neurotoxicity (MESH:D020258), chronic inflammation (MESH:D007249), Chagas disease (MESH:D014355), malaria (MESH:D008288), immune dysregulation (OMIM:614878), HIV (MESH:D015658), inflammatory cytokines (MESH:D000080424), inflammatory bowel disease (MESH:D015212), tuberculosis (MESH:D014376), systemic (MESH:D015619), neurocognitive impairment (MESH:D019965), infection (MESH:D007239), immune dysfunction (MESH:D007154), co-infections (MESH:D060085), persistent viraemia (MESH:D000088562), rheumatoid arthritis (MESH:D001172)
- **Chemicals:** DTG (MESH:C562325)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Human immunodeficiency virus 2 (no rank) [taxon 11709], Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus (species) [taxon 12721]
- **Cell lines:** RPE — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_4388)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929546/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929546/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929546/full.md

---
Source: https://tomesphere.com/paper/PMC12929546